ClinicalTrials.gg
RecruitingNCT04868526Updated Nov 17, 2026

Dietary Intervention to Mitigate Adverse Consequences of Night Work

An interventional study of dietary intervention in Dietary Habits, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 7 months later.
Updated Nov 17, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 333 studies in Feeding Behavior with a site in United States — 46 open to participants now, 66 under way, 1 of them phase 3. Feeding Behavior · United States.

Planned enrollment
226th of 271
24 · median 61
Started
2023
with 32 others
No phase
260 of 333
36 open now
Primary completion
2027-02
later than 25 of 65 live
Registered
199th of 333
by date
Lead sponsor
6 of 333
Brigham and Women's Hospital

Among the 333 studies in Feeding Behavior with a site in United States, this one is the 226th largest by planned enrollment of the 271 interventional ones that give a count, is one of 33 that started in 2023, is one of 260 with no phase, reaches primary completion later than 25 of the 65 other live ones, and was the 199th registered.

Feeding Behavior

988 studies on the registry are indexed under Feeding Behavior; 177 are open to participants now.

Browse Feeding Behavior studies →

Open to participants now

46 of the 333 studies in Feeding Behavior with a site in United States are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 112 Feeding Behavior studies recruiting now, 35 (31%) set no upper age limit and 71 (63%) stop at 75 or younger; 41 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 333 studies in Feeding Behavior with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test whether our dietary intervention can prevent or lessen the negative health effects of night shift work in healthy participants.

Participants will:

  • complete 2 inpatient stays
  • be provided with identical meals
  • have frequent blood draws
  • provide urine, saliva, stool and rectal swab samples
Read the detailed description

Shift work increases the risk for diabetes possibly due to the adverse metabolic effects of circadian misalignment. As shift work is not foreseen to disappear, the development of individually-targeted therapies for metabolic health in these vulnerable shift workers is urgently needed. This research will determine whether our dietary intervention can mitigate the adverse metabolic effects of circadian misalignment, which may help in the design of evidence-based dietary interventions to improve the metabolic health in shift workers.

03

Conditions studied

  • Dietary Habits

Browse trials for

Keywords

  • Night shift work
  • Glucose tolerance
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-45 yr old
  • 20.0-29.9
  • European/Hispanic/African-American ancestry
  • No acute, chronic or debilitating medical conditions (e.g. metabolic, cardiovascular, respiratory, neurological, cancers, etc.)

Exclusion criteria

Exclusion Criteria:

  • Currently smoking/vaping or 5 or more years of smoking/vaping
  • History of drug or alcohol dependency
  • History of psychiatric illness or disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Control-Dietary Intervention

    Control condition first, then the Dietary intervention. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage but will be made public once enrollment closes.

    Behavioral: dietary intervention

  • Experimental
    Dietary intervention-Control

    Dietary intervention first, then the Control condition. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage but will be made public once enrollment closes.

    Behavioral: dietary intervention

Interventions

  • Behavioraldietary intervention

    Research participants will be assigned to two dietary conditions.

06

What researchers measure

Primary outcomes

  1. Change in glucose tolerance from Baseline to Test Day

    Change in incremental glucose area under the curve (AUC) from a mixed meal test.

    Time frame: Baseline (Day 2) and Test Day (Day 4)

  2. Changes in microbial community structure/composition/function of oral and gut microbiome from Baseline to Test Day

    Shotgun metagenomics sequencing or 16S rRNA sequencing of saliva, stool, and rectal swab samples will provide in-depth interrogation of the microbial community structure, composition, and function.

    Time frame: Baseline (Day 2) and Test Day (Day 4)

Secondary outcomes

  1. Change in insulin sensitivity (Oral Minimal Model method) from Baseline to Test Day

    Oral Minimal Model method estimates insulin sensitivity based on blood glucose and insulin levels from a mixed meal test.

    Time frame: Baseline (Day 2) and Test Day (Day 4)

  2. Change in levels of serum markers of gut microbiota from Baseline to Test Day

    Levels of markers of gut microbiota (e.g. short chain fatty acids) will be measured in serum samples taken 3-hourly over 24 hr.

    Time frame: Baseline (Day 2) and Test Day (Day 4)

  3. Change in levels of serum markers of intestinal barrier integrity from Baseline to Test Day

    Levels of markers of intestinal barrier integrity (e.g. zonulin, LPS, LBP) will be measured in serum samples taken 3-hourly over 24 hr.

    Time frame: Baseline (Day 2) and Test Day (Day 4)

  4. Change in level of serum markers of inflammatory state from Baseline to Test Day

    Levels of markers of inflammatory state (e.g., cytokines) will be measured in serum samples taken 3-hourly over 24 hr.

    Time frame: Baseline (Day 2) and Test Day (Day 4)

07

Study locations

1 of 1 sites recruiting
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
    • Han-Chow Koh, PhD · Contact6172780924
    • Frank Scheer, PhD · Principal investigator
    • Han-Chow Koh, PhD · Sub investigator
    • Jingyi Qian, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Feb 2027, 46 months after the start.

Of 503 non-industry interventional studies with no phase under Feeding Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's planned 46 months is above that.

Counting every sponsor, half of 515 studies reached it within 14 months; a quarter within 5 and three quarters within 31.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Sep 2026 → Feb 2027 and completion Sep 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2021
First posted
May 3, 2021
StartActual
Mar 29, 2023
Primary completionEst.
Feb 28, 2027was Sep 2026
CompletionEst.
Feb 28, 2027was Sep 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 1, 2026→Feb 28, 2027
Nov 17, 2026
Study completion
Sep 1, 2026→Feb 28, 2027
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Sep 1, 2026→Feb 28, 2027
    Study completion Sep 1, 2026→Feb 28, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04868526
Responsible party
Frank AJL Scheer, PhD (Professor, Brigham and Women's Hospital) — Principal investigator
First posted
May 3, 2021
Start date
Mar 29, 2023
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Megan Munn
Contact
mmunn@bwh.harvard.edu
6175258259
Han-Chow Koh, PhD
Contact
hkoh@bwh.harvard.edu
6172780924
Frank Scheer, PhD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion